FY2024 Earnings Forecast for Agenus Issued By William Blair

Agenus Inc. (NASDAQ:AGEN) – Investment analysts at William Blair boosted their FY2024 earnings per share (EPS) estimates for Agenus in a research report issued to clients and investors on Monday, January 27th. William Blair analyst M. Phipps now anticipates that the biotechnology company will post earnings per share of ($14.59) for the year, up from their prior estimate of ($15.34). The consensus estimate for Agenus’ current full-year earnings is ($12.93) per share. William Blair also issued estimates for Agenus’ Q4 2024 earnings at ($2.37) EPS, Q1 2025 earnings at ($1.31) EPS, Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($0.85) EPS, Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($3.92) EPS, FY2026 earnings at ($2.91) EPS and FY2027 earnings at ($2.83) EPS.

Separately, HC Wainwright restated a “neutral” rating on shares of Agenus in a research note on Wednesday, January 22nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $10.00.

Agenus Trading Down 1.9 %

Shares of NASDAQ AGEN opened at $3.54 on Thursday. The company has a market capitalization of $83.05 million, a price-to-earnings ratio of -0.31 and a beta of 1.27. Agenus has a twelve month low of $2.50 and a twelve month high of $19.69. The business has a 50 day simple moving average of $3.24 and a 200-day simple moving average of $4.61.

Institutional Trading of Agenus

Institutional investors have recently added to or reduced their stakes in the business. HighTower Advisors LLC lifted its holdings in shares of Agenus by 46.1% during the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after buying an additional 7,530 shares during the last quarter. FMR LLC raised its stake in Agenus by 47.1% during the 3rd quarter. FMR LLC now owns 85,301 shares of the biotechnology company’s stock valued at $467,000 after purchasing an additional 27,309 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Agenus by 2,271.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 39,533 shares of the biotechnology company’s stock valued at $217,000 after purchasing an additional 37,866 shares during the period. Geode Capital Management LLC grew its position in Agenus by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock worth $2,648,000 after purchasing an additional 32,016 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Agenus by 2.1% during the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock worth $2,563,000 after purchasing an additional 9,731 shares during the period. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.